168 related articles for article (PubMed ID: 37097724)
1. Effectiveness of the Lilly Connected Care Program in Improving Glycemic Management Among Patients With Type 2 Diabetes in China: Retrospective Real-world Study.
Su B; Chen Y; Shen X; Guo J; Ding Y; Ma X; Yang Y; Liu D
J Med Internet Res; 2023 Apr; 25():e38680. PubMed ID: 37097724
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of the Family Portal Function on the Lilly Connected Care Program (LCCP) for Patients With Type 2 Diabetes: Retrospective Cohort Study With Propensity Score Matching.
Zhang Y; Liu C; Luo S; Huang J; Yang Y; Ma X; Li X; Zhou Z
JMIR Mhealth Uhealth; 2021 Feb; 9(2):e25122. PubMed ID: 33544081
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of Lilly Connected Care Program (LCCP) App-Based Diabetes Education for Patients With Type 2 Diabetes Treated With Insulin: Retrospective Real-World Study.
Zhang Y; Liu C; Luo S; Huang J; Li X; Zhou Z
JMIR Mhealth Uhealth; 2020 Mar; 8(3):e17455. PubMed ID: 32141838
[TBL] [Abstract][Full Text] [Related]
4. Achieving comparability in glycemic control between antidiabetic treatment strategies in pregnancy when using real world data.
Cesta CE; Hernández-Díaz S; Huybrechts KF; Bateman BT; Vine S; Seely EW; Patorno E
Pharmacoepidemiol Drug Saf; 2023 Dec; 32(12):1350-1359. PubMed ID: 37461243
[TBL] [Abstract][Full Text] [Related]
5. Correlation between baseline characteristics and clinical outcomes in a large population of diabetes patients treated with liraglutide in a real-world setting in Italy.
Lapolla A; Frison V; Bettio M; Dal Pos M; Rocchini P; Panebianco G; Tadiotto F; Da Tos V; D'Ambrosio M; Marangoni A; Ferrari M; Pianta A; Balzano S; Confortin L; Lamonica M; Marin N; Strazzabosco M; Brun E; Mesturino CA; Simoncini M; Zen F; Bax G; Bonsembiante B; Cardone C; Dal Frà MG; Gallo A; Masin M; Piarulli F; Sartore G; Simioni N
Clin Ther; 2015 Mar; 37(3):574-84. PubMed ID: 25626486
[TBL] [Abstract][Full Text] [Related]
6. Exenatide Once Weekly: Effectiveness, Tolerability, and Discontinuation Predictors in a Real-world Setting.
Di Dalmazi G; Coluzzi S; Baldassarre MPA; Sorbo SE; Dell'Aquila S; Febo F; Ginestra F; Graziano G; Rossi MC; Consoli A; Formoso G
Clin Ther; 2020 Sep; 42(9):1738-1749.e1. PubMed ID: 32753164
[TBL] [Abstract][Full Text] [Related]
7. Clinical and economic outcomes among injection-naïve patients with type 2 diabetes initiating dulaglutide compared with basal insulin in a US real-world setting: the DISPEL Study.
Mody R; Huang Q; Yu M; Patel H; Zhang X; Wang L; Grabner M
BMJ Open Diabetes Res Care; 2019; 7(1):e000884. PubMed ID: 31875137
[TBL] [Abstract][Full Text] [Related]
8. Patient characteristics and 6-month dose of basal insulin associated with HbA1c achievement <7.0% in Chinese people with type 2 diabetes: results from the Observational Registry of Basal Insulin Treatment (ORBIT).
Gao L; Zhang P; Weng J; Lu J; Guo X; Jia W; Yang W; Zou D; Zhou Z; Pan C; Gao Y; Li X; Zhu D; Wu Y; Garg SK; Ji L
J Diabetes; 2020 Sep; 12(9):668-676. PubMed ID: 32329194
[TBL] [Abstract][Full Text] [Related]
9. Predictors of poor glycemic control among type 2 diabetes mellitus patients treated with antidiabetic medications: A cross-sectional study in China.
Wang J; Li J; Wen C; Liu Y; Ma H
Medicine (Baltimore); 2021 Oct; 100(43):e27677. PubMed ID: 34713865
[TBL] [Abstract][Full Text] [Related]
10. A Mobile-Based Intervention for Glycemic Control in Patients With Type 2 Diabetes: Retrospective, Propensity Score-Matched Cohort Study.
Li J; Sun L; Wang Y; Guo L; Li D; Liu C; Sun N; Xu Z; Li S; Jiang Y; Wang Y; Zhang S; Chen L
JMIR Mhealth Uhealth; 2020 Mar; 8(3):e15390. PubMed ID: 32159518
[TBL] [Abstract][Full Text] [Related]
11. Glycemic control and safety in Chinese patients with type 2 diabetes mellitus who switched from premixed insulin to insulin glargine plus oral antidiabetics: a large, prospective, observational study.
Zhang B; Zhao J; Yang W;
Diabetes Metab Res Rev; 2017 Mar; 33(3):. PubMed ID: 27667797
[TBL] [Abstract][Full Text] [Related]
12. Effects of basal and premixed insulin on glycemic control in type 2 diabetes patients based on multicenter prospective real-world data.
Peng Y; Xu P; Shi J; Zhang Y; Wang S; Zheng Q; Wang Y; Ke T; Li L; Zhao D; Dai Y; Dong Q; Ji B; Xu F; Gu W; Wang W
J Diabetes; 2022 Feb; 14(2):134-143. PubMed ID: 35023626
[TBL] [Abstract][Full Text] [Related]
13. Utilizing Technology-Enabled Intervention to Improve Blood Glucose Self-Management Outcome in Type 2 Diabetic Patients Initiated on Insulin Therapy: A Retrospective Real-World Study.
Lin J; Li X; Jiang S; Ma X; Yang Y; Zhou Z
Int J Endocrinol; 2020; 2020():7249782. PubMed ID: 33224195
[TBL] [Abstract][Full Text] [Related]
14. Baseline and 1-year interim follow-up assessment of Japanese patients initiating insulin therapy who were enrolled in the cardiovascular risk evaluation in people with type 2 diabetes on insulin therapy study: an international, multicenter, observational study.
Kawamori R; Node K; Hanafusa T; Atsumi Y; Naito Y; Oka Y
Cardiovasc Diabetol; 2013 Sep; 12():131. PubMed ID: 24011395
[TBL] [Abstract][Full Text] [Related]
15. Treatment patterns and satisfaction in patients with type 2 diabetes newly initiating oral monotherapy with antidiabetic drugs in Japan: results from the prospective Real-world Observational Study on Patient Outcomes in Diabetes (RESPOND).
Tajima A; Tobe K; Eiki JI; Origasa H; Watada H; Shimomura I; Tokita S; Kadowaki T
BMJ Open Diabetes Res Care; 2022 Dec; 10(6):. PubMed ID: 36585033
[TBL] [Abstract][Full Text] [Related]
16. Real-world evaluation of glycemic control among patients with type 2 diabetes mellitus treated with canagliflozin versus dipeptidyl peptidase-4 inhibitors.
Thayer S; Chow W; Korrer S; Aguilar R
Curr Med Res Opin; 2016 Jun; 32(6):1087-96. PubMed ID: 26938635
[TBL] [Abstract][Full Text] [Related]
17. Dulaglutide Shows Sustained Reduction in Glycosylated Hemoglobin Values: 2-Year US Real-world Study Results.
Mody R; Yu M; Grabner M; Boye K; Teng CC; Kwan AYM
Clin Ther; 2020 Nov; 42(11):2184-2195. PubMed ID: 33256915
[TBL] [Abstract][Full Text] [Related]
18. HBA1C CONTROL AND COST-EFFECTIVENESS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS INITIATED ON CANAGLIFLOZIN OR A GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONIST IN A REAL-WORLD SETTING.
Wysham CH; Pilon D; Ingham M; Lafeuille MH; Emond B; Kamstra R; Pfeifer M; Lefebvre P
Endocr Pract; 2018 Mar; 24(3):273-287. PubMed ID: 29547044
[TBL] [Abstract][Full Text] [Related]
19. Individualized HbA
Lautsch D; Boggs R; Wang T; Gonzalez C; Milligan G; Rajpathak S; Malkani S; McLeod E; Carroll J; Higgins V
Adv Ther; 2022 Feb; 39(2):1016-1032. PubMed ID: 34951678
[TBL] [Abstract][Full Text] [Related]
20. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
